{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000047","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.310613+00:00","generated_at":"2026-06-01T04:01:06.880064+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ligand reports Merck vaccine FDA approval milestone and Takeda soticlestat Phase 3 miss","bullets":["FDA approved Merck's CAPVAXIVE; Ligand earns $2M milestone + royalties on net sales.","Takeda's soticlestat missed primary endpoints in Dravet (SKYLINE) and Lennox-Gastaut (SKYWAY) Phase 3 trials.","Ligand owns 13% royalty on soticlestat from $30M Ovid deal; clinical miss reduces royalty value.","SKYLINE narrowly missed seizure reduction primary; showed significant secondary endpoint effects.","SKYWAY missed primary endpoint of reduction in major motor drop seizures."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000047","json":"https://secwatch.observer/filing/0000886163-24-000047.json","markdown":"https://secwatch.observer/filing/0000886163-24-000047.md","text":"https://secwatch.observer/filing/0000886163-24-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000047/0000886163-24-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000047/lgnd-20240618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:01:06.880064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}